-
1.发明申请THERAPEUTIC AGENT, TREATMENT METHOD AND INSPECTION METHOD FOR DISEASES CAUSED BY ACTIVATION OR NEUTROPHILS 有权治疗药物，治疗方法和检查方法由激活或中性粒细胞引起的疾病公开(公告)号：US20150141322A1
公开(公告)日：2015-05-21
申请号：US14406191
申请日：2013-05-28
发明人： Masahiro Nishibori , Shuji Mori , Hidenori Wake , Hideo Takahashi , Keyue Liu , Kiyoshi Teshigawara , Masakiyo Sakaguchi
CPC分类号： A61K38/1709 , A61K38/00 , G01N33/6893 , G01N2800/067 , G01N2800/125 , G01N2800/26
摘要： The present invention provides a therapeutic agent, a treatment method and an inspection method for diseases caused by activation of neutrophils. More specifically, the invention relates to a neutrophil activation regulator which comprising a histidine-rich glycoprotein (HRG) as an active ingredient, and provides a therapeutic agent for diseases caused by neutrophil activation comprising the neutrophil activation regulator, a treatment method for diseases caused by neutrophil activation, and further an inspection method for diseases caused by neutrophil activation. The present invention is based on the neutrophil activation regulator including the HRG as an active ingredient. The present invention extends to the depressant agent for neutrophil-vascular endothelial cell interaction including the HRG of the present invention as an active ingredient, the treatment method for diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation. The present invention also extends to the inspection method for inflammatory diseases accompanied by neutrophil activation by measuring the blood HRG level.
摘要翻译： 本发明提供了由嗜中性粒细胞活化引起的疾病的治疗剂，治疗方法和检查方法。 更具体地，本发明涉及一种嗜中性粒细胞活化调节剂，其包含富含组氨酸的糖蛋白（HRG）作为活性成分，并且提供由嗜中性粒细胞活化引起的疾病引起的治疗剂，包括嗜中性粒细胞活化调节剂，由 嗜中性粒细胞激活，还有一种由嗜中性粒细胞激活引起的疾病的检查方法。 本发明基于包含HRG作为活性成分的嗜中性粒细胞活化调节剂。 本发明延伸到嗜中性粒细胞 - 血管内皮细胞相互作用的抑制剂，包括本发明的HRG作为活性成分，由嗜中性粒细胞活化引起的疾病和/或伴有中性粒细胞活化的炎性疾病的治疗方法。 本发明还延伸到通过测量血液HRG水平伴随嗜中性粒细胞活化的炎性疾病的检查方法。
-
2.发明授权Therapeutic agent, treatment method and inspection method for diseases caused by activation of neutrophils 有权中性粒细胞活化引起的疾病的治疗剂，治疗方法和检查方法公开(公告)号：US09504731B2
公开(公告)日：2016-11-29
申请号：US14406191
申请日：2013-05-28
发明人： Masahiro Nishibori , Shuji Mori , Hidenori Wake , Hideo Takahashi , Keyue Liu , Kiyoshi Teshigawara , Masakiyo Sakaguchi
CPC分类号： A61K38/1709 , A61K38/00 , G01N33/6893 , G01N2800/067 , G01N2800/125 , G01N2800/26
摘要： The present invention provides a therapeutic agent, a treatment method and an inspection method for diseases caused by activation of neutrophils. More specifically, the invention relates to a neutrophil activation regulator which comprising a histidine-rich glycoprotein (HRG) as an active ingredient, and provides a therapeutic agent for diseases caused by neutrophil activation comprising the neutrophil activation regulator, a treatment method for diseases caused by neutrophil activation, and further an inspection method for diseases caused by neutrophil activation. The present invention is based on the neutrophil activation regulator including the HRG as an active ingredient. The present invention extends to the depressant agent for neutrophil-vascular endothelial cell interaction including the HRG of the present invention as an active ingredient, the treatment method for diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation. The present invention also extends to the inspection method for inflammatory diseases accompanied by neutrophil activation by measuring the blood HRG level.
摘要翻译： 本发明提供了由嗜中性粒细胞活化引起的疾病的治疗剂，治疗方法和检查方法。 更具体地，本发明涉及一种嗜中性粒细胞活化调节剂，其包含富含组氨酸的糖蛋白（HRG）作为活性成分，并且提供由嗜中性粒细胞活化引起的疾病引起的治疗剂，包括嗜中性粒细胞活化调节剂，由 嗜中性粒细胞激活，还有一种由嗜中性粒细胞激活引起的疾病的检查方法。 本发明基于包含HRG作为活性成分的嗜中性粒细胞活化调节剂。 本发明延伸到嗜中性粒细胞 - 血管内皮细胞相互作用的抑制剂，包括本发明的HRG作为活性成分，由嗜中性粒细胞活化引起的疾病和/或伴有中性粒细胞活化的炎性疾病的治疗方法。 本发明还延伸到通过测量血液HRG水平伴随嗜中性粒细胞活化的炎性疾病的检查方法。
-
公开(公告)号：US09696321B2
公开(公告)日：2017-07-04
申请号：US14995679
申请日：2016-01-14
发明人： Kosuke Kuroda , Hiroshi Morimatsu , Hidenori Wake , Shuji Mori , Masahiro Nishibori , Hideo Takahashi , Keyue Liu , Kiyoshi Teshigawara , Masakiyo Sakaguchi
CPC分类号： G01N33/6893 , G01N2800/24 , G01N2800/26 , G01N2800/52 , G01N2800/56
摘要： The present invention provides a neutrophil activation regulator comprising a histidine-rich glycoprotein (HRG) for the treatment of systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation in a subject in need thereof. Further, the present invention provides methods for predicting the severity of systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation in a subject in need thereof, and methods for predicting the survival of a subject with systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation, that comprise determining the blood level of histidine-rich glycoprotein in the subject.
-
-
搜索结果
3 条记录 (耗时 0.014 秒)
